By directly controlling the activation of these kinases, LKB1 inhibits mammalian target of rapamycin (mTOR), a tumor‐promoting kinase, and activates tuberous sclerosis 2 (TSC2) and p53, both of which are tumor suppressors 16, 18, 19, 20, 21. Here, TSC2 is linked to neoplasm.